StockNews.com Begins Coverage on Aptevo Therapeutics (NASDAQ:APVO)

Stock analysts at StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a report issued on Thursday. The firm set a “sell” rating on the biotechnology company’s stock.

Aptevo Therapeutics Stock Performance

Shares of NASDAQ APVO opened at $0.71 on Thursday. Aptevo Therapeutics has a 52 week low of $0.70 and a 52 week high of $91.96. The stock’s fifty day moving average is $4.90 and its 200 day moving average is $7.90.

Institutional Trading of Aptevo Therapeutics

Several large investors have recently bought and sold shares of the business. Citadel Advisors LLC acquired a new stake in Aptevo Therapeutics in the fourth quarter valued at about $47,000. Sabby Management LLC acquired a new stake in Aptevo Therapeutics in the third quarter valued at about $440,000. Armistice Capital LLC acquired a new stake in Aptevo Therapeutics in the third quarter valued at about $408,000. Cantor Fitzgerald L. P. boosted its stake in Aptevo Therapeutics by 14.8% in the second quarter. Cantor Fitzgerald L. P. now owns 251,122 shares of the biotechnology company’s stock valued at $367,000 after buying an additional 32,422 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Aptevo Therapeutics by 45.8% in the second quarter. Renaissance Technologies LLC now owns 80,186 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 25,200 shares in the last quarter. 8.06% of the stock is owned by institutional investors and hedge funds.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and.